{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:53Z","timestamp":1787014133810,"version":"build-2736575974"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To report interim data from TAURUS, a study assessing real\u2010world prophylactic treatment with unmodified, full\u2010length recombinant FVIII BAY 81\u20108973 (Kovaltry\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ; Bayer) indicated for haemophilia A.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TAURUS (NCT02830477) is an international, open\u2010label, prospective, non\u2010interventional, single\u2010arm study with a one\u2010year observation period (target N\u00a0=\u00a0350). Patients have moderate or severe haemophilia A (FVIII \u22645% or \u22641%) and \u226550 exposure days to any FVIII product. Clinician\u2010 and patient\u2010reported outcomes are captured on previous product use, changes in prophylaxis dose and dosing frequency, FVIII consumption, reported bleeding rates, treatment satisfaction and adherence, pharmacokinetic (PK) data (if available) and safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At cut\u2010off, baseline data were available from 160 patients (89 had \u22656\u00a0months of follow\u2010up data). Most patients had severe haemophilia A (85%), infused BAY 81\u20108973\u00a0\u2265\u00a03\u00d7\/wk (59%) and experienced a median number of total bleeds of 2.0 (non\u2010annualised; 246\u00a0days median documentation period). Good levels of treatment satisfaction (Hemo\u2010SAT\n                      <jats:sub>A,P<\/jats:sub>\n                      ) and adherence (VERITAS\u2010Pro) were maintained. TAURUS demonstrated a favourable PK profile of BAY 81\u20108973 in comparison with other standard half\u2010life rFVIIIs and supported the WAPPS PopPK model. No patients developed inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TAURUS data demonstrate effective prophylaxis with BAY 81\u20108973 in the real world without compromising patient satisfaction or adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.13420","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T14:21:07Z","timestamp":1586269267000},"page":"164-172","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["BAY 81\u20108973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-447X","authenticated-orcid":false,"given":"Cristina","family":"Santoro","sequence":"first","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng","family":"Fuh","sequence":"additional","affiliation":[{"name":"East Carolina University Greenville NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phu Quoc","family":"Le","sequence":"additional","affiliation":[{"name":"Queen Fabiola Children's University Hospital Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Maes","sequence":"additional","affiliation":[{"name":"University Hospital of Antwerp Edegem Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Berrueco","sequence":"additional","affiliation":[{"name":"Hospital Sant Joan de D\u00e9u Barcelona University Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Mingot\u2010Castellano","sequence":"additional","affiliation":[{"name":"Hospital Regional Universitario de M\u00e1laga M\u00e1laga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"von Mackensen","sequence":"additional","affiliation":[{"name":"Department of Medical Psychology University Medical Centre Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Solms","sequence":"additional","affiliation":[{"name":"Bayer Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Colorado Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6050054"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_7_4_1","unstructured":"Bayer Healthcare.Kovaltry prescribing information.2016.https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/bloodbloodproducts\/approvedproducts\/licensedproductsblas\/fractionatedplasmaproducts\/ucm491119.pdf. Accessed March 2019."},{"key":"e_1_2_7_5_1","unstructured":"Bayer HealthCare.Kovaltry summary of product characteristics.2016.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kovaltry\u2010epar\u2010product\u2010information_en.pdf. Accessed March 2019."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12866"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12952"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12828"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12691"},{"issue":"1","key":"e_1_2_7_10_1","first-page":"PB 971","article-title":"Improved pharmacokinetics of BAY 81\u20138973 versus sucrose\u2010formulated recombinant factor VIII (rFVIII\u2010FS): noncompartmental and population PK assessment based on a single\u2010dose, randomized, crossover, pharmacokinetics study in patients with severe hemophilia A","volume":"1","author":"Solms A","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0492-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S188171"},{"key":"e_1_2_7_13_1","unstructured":"Bayer HealthCare.Data on file. PSUR\/PBRER Kovaltry review cycle 32 Aug 2019. In:2019."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12925"},{"key":"e_1_2_7_15_1","unstructured":"World Health Organization.Adherence to long\u2010term therapies: Evidence for action.2003.https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_full_report.pdf. Accessed April 1 2019."},{"issue":"3","key":"e_1_2_7_16_1","first-page":"126","article-title":"Development and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo\u2010SatA)","volume":"10","author":"Mackensen S","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-78665-0_112"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02129.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6559"},{"key":"e_1_2_7_20_1","unstructured":"BayerAG.Kogenate Bayer summary of product characteristics.2018.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kogenate\u2010bayer\u2010epar\u2010product\u2010information_en.pdf. Accessed April 2019."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12113"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12618"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01189.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01526.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12631"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-06-0409"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13733"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1214711"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T12:27:38Z","timestamp":1693916858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/ejh.13420"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13420","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"2019-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}